The healthcare sector delivered strong growth in Q2 FY26, with top-line revenue increasing by 19% YoY and 8% QoQ.

(Photo Source: freepik) The pharmaceutical universe under Axis Securities' coverage reported Q2 FY26 growth of 11.9% YoY and 6.2% QoQ, supported by strong India business performance (+8.5% YoY). The US business remained flat, up only 1% in CC terms, led by Lupin’s gTolvaptan and Emerging Markets. The healthcare sector delivered strong performance in Q2 FY26, with top-line revenue rising 19% YoY and 8% QoQ.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In

See Full Page